Details for New Drug Application (NDA): 009296
✉ Email this page to a colleague
NDA 009296 describes SERPASIL-APRESOLINE, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the SERPASIL-APRESOLINE profile page.
The generic ingredient in SERPASIL-APRESOLINE is hydralazine hydrochloride; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; reserpine profile page.
The generic ingredient in SERPASIL-APRESOLINE is hydralazine hydrochloride; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; reserpine profile page.
Summary for 009296
| Tradename: | SERPASIL-APRESOLINE |
| Applicant: | Novartis |
| Ingredient: | hydralazine hydrochloride; reserpine |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG;0.2MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;0.1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
